Krascendo 1
KRAScendo-1 asks whether divarasib can improve outcomes over sotorasib or adagrasib for people with advanced or metastatic non-small cell lung cancer bearing KRAS G12C mutations after earlier systemic treatment. Discussion covers direct comparisons between targeted agents, progression-free and overall survival, information needed to assess benefits and risks, and potential implications for treatment choices. The sources reviewed for this edition reflect commentary before the main results presentation anticipated at ESMO 2026.
- NCT06497556 ↗
- v1.0.0 · edition 1
- updated Oct 18, 2026
- Focused
4 findings, and what sits behind each
Select a finding to see what the full report holds for it: how many verified HCP statements and of what kind, the passages behind them, the sources and voices, and the counterview and limits it records. Select a part of the trial to see which findings draw on it.
- Finding 1 of 4
Favorable topline reactions do not yet constitute a full benefit–risk assessment
- statements
- 14
- passages
- 12
- sources
- 12
- named voices
- 11
What the statements areViews 2Questions and uncertainty 2Clinical experience 0Comparisons 0Restated results and context 10How passages are usedSupporting a statement 16Giving context 0Recorded with the finding- Counterview: none recorded
- Limitations: 3
- Feeds the Medical Affairs question
- 12 posts and articles
Draws on: The comparison, Primary endpoint: Progression-Free Survival (PFS), Secondary endpoints, Population and setting.
In the full report: the interpretation in full, all 14 statements cited to source and date, and the 12 sources linked where public.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap, since one statement can back several findings, and they show what the report kept, not how many clinicians agree.
The full Krascendo 1 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified HCP statements, each linked to the original. Get a complete report free to see what you get.
What efficacy, survival-maturity and tolerability details are needed before the announcement can support a complete benefit–risk discussion?
Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
free- 26HCP commentary sources screened
- 17sources cited by verified HCP statements
- 18found in screened sources
- 13matched to verified clinician profiles
- 15voices cited in the report
- 27verified HCP statements, each linked to its source
- 4findings
Screened sources were retrieved for this trial. Cited sources back at least one verified HCP statement and include primary sources used for context. No count estimates how many clinicians hold a view. Size (Focused) is set by the 27 verified HCP statements.
What's inside
free| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified HCP statements with short source quotes and links | 27 | Paid |
| Trial aspects mapped | 9 | Free |
| Sources with links | 17 | Counts free |
| Speaker attribution for cited voices | 15 | Paid |
Trial aspects
8 discussed · 1 no commentary · 0 incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Progression-Free Survival (PFS) | 6 | 7 |
| Secondary endpoints | 5 | 6 |
| Population and setting | 7 | 3 |
| The comparison | 12 | 10 |
| Safety and tolerabilityno commentary found | 0 | 0 |
| Design and conduct | 3 | 1 |
| Perceived advance and possible practice impact | 9 | 9 |
| Topline uncertainty and presentation expectations | 11 | 8 |
| Heterogeneity and possible combination strategies | 1 | 1 |
An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.
Sources
free| Channel | Screened | Cited | |
|---|---|---|---|
| X threads | 25 | 15 | |
| YouTube | 1 | 1 | |
| Primary sources, cited for context, not screened | |||
| Registry | not screened | 1 | |
max 21 / quarter
- Screened window
- Jun 26, 2024 → Oct 11, 2026
- Cited window
- Jun 18, 2026 → Oct 11, 2026
- Retrieved
- Oct 18, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
- Registry
- NCT06497556
- Study IDs
- BO45217 · 2024-510908-37-00 (EU CT Number)
- Sponsor
- Hoffmann-La Roche
- Collaborators
- Chugai Pharmaceutical
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 338 actual
- Start
- 2024-09-23 actual
- Primary completion
- 2026-05-19 actual
- Primary endpoint
- Progression-Free Survival (PFS)
- Interventions
- 3 registered
Scope and limits
freeThis report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 2 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- Most efficacy reactions describe company-announced topline findings rather than independent assessment of a full trial dataset; numerical treatment effects and substantive comparative safety commentary are unavailable here.
- No full protocol, exact-trial results publication or divarasib prescribing label was available among the sources reviewed. This does not establish that such materials do not exist.
- Discussion using unnamed references or different transcription forms may be missing, so the report is not an exhaustive account of public or clinical opinion.
- One included social-media discussion was not fully evaluated beyond the statements described in this report; additional views from it may be missing.
- Repeated posts and shared company headlines do not represent independent clinical assessments.
- The video account has no available publication date, preventing reliable chronological comparison with the dated posts.
- Chandrakanth's clinical role is not established in the sources reviewed for this edition.
How reports are built and checked: Methods.
Editions and corrections
freeLast checked for new commentary Oct 18, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.
Cite this report
Erudio Health. Krascendo 1 (NCT06497556): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 18, 2026. https://www.erudio.com/reports/krascendo-1-nct06497556
For your AI agent
The same record as JSON or Markdown, or through the Erudio MCP server
curl https://www.erudio.com/reports/krascendo-1-nct06497556.json
curl https://www.erudio.com/reports/krascendo-1-nct06497556.md
# MCP (https://mcp.erudio.com/mcp)
get_report_card({ "slug": "krascendo-1-06497556" })release 2af386ac68ea7ed0efc2c6a281e086892c6f2bb7123627e3b7921fe04daa3abb